Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., & June, C. H. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134

Article  CAS  PubMed  Google Scholar 

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., . . . Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758

Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., Bories, P., Bay, J. O., Llorente, C. C., Choquet, S., Casasnovas, R. O., Mohty, M., Guidez, S., Joris, M., Loschi, M., . . . Morschhauser, F. (2022). A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine, 28(10), 2145–2154. https://doi.org/10.1038/s41591-022-01969-y

Frigault, M. J., Amoloja, T., Burke, L. M., Morariu-Zamfir, R., Bhatt, V., Bibeau, K., Tang, X. Y., Moskop, A., Maziarz, R. T., & DiPersio, J. F. (2023). Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T). Journal of Clinical Oncology, 41(16_suppl), 7528–7528. https://doi.org/10.1200/JCO.2023.41.16_suppl.7528

Article  Google Scholar 

Brammer, J. E., Braunstein, Z., Katapadi, A., Porter, K., Biersmith, M., Guha, A., Vasu, S., Yildiz, V. O., Smith, S. A., Buck, B., Haddad, D., Gumina, R., William, B. M., Penza, S., Saad, A., Denlinger, N., Vallakati, A., Baliga, R., Benza, R., . . . Addison, D. (2021). Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. Journal for Immunotherapy of Cancer, 9(8). https://doi.org/10.1136/jitc-2020-002303

Tang, K., & Nastoupil, L. J. (2021). Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: How similar are they to the prospective studies? J Immunother Precis Oncol, 4(3), 150–159. https://doi.org/10.36401/jipo-21-2

Westin, J. R., Kersten, M. J., Salles, G., Abramson, J. S., Schuster, S. J., Locke, F. L., & Andreadis, C. (2021). Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. American Journal of Hematology, 96(10), 1295–1312. https://doi.org/10.1002/ajh.26301

Article  PubMed  PubMed Central  Google Scholar 

Pasquini, M. C., Hu, Z. H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., Salzberg, D., Jaglowski, S., Sasine, J. P., Rosenthal, J., Ghosh, M., Landsburg, D., Margossian, S., Martin, P. L., Kamdar, M. K., . . . Grupp, S. (2020). Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 4(21), 5414–5424. https://doi.org/10.1182/bloodadvances.2020003092

Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., Fry, T. J., Holter-Chakrabarty, J. L., Komanduri, K. V., Lee, D. W., Locke, F. L., Maude, S. L., McCarthy, P. L., Mead, E., Neelapu, S. S., . . . Grupp, S. A. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001511

Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Barz Leahy, A., Callahan, C., Dolan, J. G., Fitzgerald, J. C., Gladney, W., Lacey, S. F., Liu, H., Maude, S. L., McGuire, R., Motley, L. S., Teachey, D. T., Wertheim, G. B., Wray, L., . . . Grupp, S. A. (2021). Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. Journal of Clinical Oncology, 39(8), 920–930. https://doi.org/10.1200/jco.20.02477

Kittai, A. S., Huang, Y., Gordon, M., Denlinger, N., Mian, A., Fitzgerald, L., Bishop, J., Nagle, S., Stephens, D. M., Jaglowski, S., Hill, B., & Danilov, A. V. (2021). Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: A multicenter analysis. Transplantation and Cellular Therapy, 27(1), 46–52. https://doi.org/10.1016/j.bbmt.2020.09.028

Article  CAS  PubMed  Google Scholar 

Santomasso, B. D., Gust, J., & Perna, F. (2023). How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood, 141(20), 2443–2451. https://doi.org/10.1182/blood.2022017604

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aghajan, Y., Yu, A., Jacobson, C. A., Kim, A. I., Kean, L., Robertson, M., & Vaitkevicius, H. (2021). Myelopathy because of CAR-T-related neurotoxicity treated with siltuximab. Neurology: Clinical Practice, 11(6), e944–e946. https://doi.org/10.1212/cpj.0000000000001078

Article  PubMed  Google Scholar 

Shalabi, H., Harrison, C., Yates, B., Calvo, K. R., Lee, D. W., & Shah, N. N. (2024). Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome. Pediatric Blood & Cancer, 71(1), e30741. https://doi.org/10.1002/pbc.30741

Article  CAS  Google Scholar 

Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N., Arnulf, B., Mateos, M. V., Lendvai, N., Jackson, C. C., De Braganca, K. C., Schecter, J. M., Marquez, L., Lee, E., Cornax, I., Zudaire, E., Li, C., Olyslager, Y., Madduri, D., Varsos, H., . . . Jagannath, S. (2022). Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 12(2), 32. https://doi.org/10.1038/s41408-022-00629-1

Hill, J. A., & Seo, S. K. (2020). How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 136(8), 925–935. https://doi.org/10.1182/blood.2019004000

Article  PubMed  PubMed Central  Google Scholar 

Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, G. M., Marsh, R. A., Neelapu, S. S., Nikiforow, S., Ombrello, A. K., Shah, N. N., Talleur, A. C., . . . Shah, N. N. (2023). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy, 29(7), 438.e431–438.e416. https://doi.org/10.1016/j.jtct.2023.03.006

Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M. C., Fagioli, F., Ahlmann, M., Dapena Diaz, J. L., Henry, M., De Benedetti, F., Grom, A., Lapeyre, G., Jacqmin, P., Ballabio, M., & de Min, C. (2020). Emapalumab in children with primary hemophagocytic lymphohistiocytosis. New England Journal of Medicine, 382(19), 1811–1822. https://doi.org/10.1056/NEJMoa1911326

Article  PubMed  Google Scholar 

Porter, T. J., Lazarevic, A., Ziggas, J. E., Fuchs, E., Kim, K., Byrnes, H., Luznik, L., Bolaños-Meade, J., Ali, S. A., Shah, N. N., Wagner-Johnston, N., & Jain, T. (2022). Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. British Journal of Haematology, 199(5), 720–727. https://doi.org/10.1111/bjh.18454

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., Ciceri, F., Corradini, P., Delgado, J., Di Blasi, R., Greco, R., Houot, R., Iacoboni, G., Jäger, U., Kersten, M. J., . . . Yakoub-Agha, I. (2023). Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood, 142(10), 865–877. https://doi.org/10.1182/blood.2023020578

McNerney, K. O., Si Lim, S. J., Ishikawa, K., Dreyzin, A., Vatsayan, A., Chen, J. J., Baggott, C., Prabhu, S., Pacenta, H. L., Philips, C., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Verneris, M., Myers, D., Karras, N. A., Brown, P., Bonifant, C. L., . . . Schultz, L. M. (2023). HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Advances, 7(12), 2758–2771. https://doi.org/10.1182/bloodadvances.2022008893

Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, E., Weng, W. K., Shiraz, P., Rezvani, A., Latchford, T., Mackall, C., Miklos, D., . . . Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 5(21), 4465–4475. https://doi.org/10.1182/bloodadvances.2021004716

Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., Gust, J., Lim, M., Majzner, R. G., Park, J. R., Partap, S., Ramakrishna, S., Richards, R., Schultz, L., Vitanza, N. A., . . . Monje, M. (2023). Tumor inflammation-associated neurotoxicity. Nature Medicine, 29(4), 803–810. https://doi.org/10.1038/s41591-023-02276-w

Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, A. Y., Gillespie, S. M., Toland, A. M. S., Mahdi, J., Reschke, A., Nie, E. H., Chau, I. J., . . . Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934–941. https://doi.org/10.1038/s41586-022-04489-4

Appa, A. A., Jain, R., Rakita, R. M., Hakimian, S., & Pottinger, P. S. (2017). Characterizing cefepime neurotoxicity: A systematic review. Open Forum Infectious Diseases, 4(4), ofx70. https://doi.org/10.1093/ofid/ofx170

Article  CAS  Google Scholar 

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., . . . Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448. https://doi.org/10.1056/NEJMoa1709866

Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., Kato, K., Harigae, H., Kersten, M. J., Andreadis, C., Riedell, P. A., Ho, P. J., Pérez-Simón, J. A., Chen, A. I., Nastoupil, L. J., . . . Thieblemont, C. (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nature Medicine, 28(2), 325–332. https://doi.org/10.1038/s41591-021-01622-0

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I., Rabitsch, W., Kwong, Y. L., Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., . . . Westin, J. R. (2022). Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med, 386(7), 629–639. https://doi.org/10.1056/NEJMoa2116596

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., . . . Maziarz, R. T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45–56. https://doi.org/10.1056/NEJMoa1804980

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., . . . Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531–2544. https://doi.org/10.1056/NEJMoa1707447

Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Yakoub-Agha, I., Oluwole, O. O., Fung, H. C. H., Rosenblatt, J., Rossi, J. M., Goyal, L., Plaks, V., . . . Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. The Lancet Haematology, 23(1), 91–103. https://doi.org/10.1016/s1470-2045(21)00591-x

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M. A., Kersten, M. J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Muñoz, J., Farooq, U., van Meerten, T., Reagan, P. M., Sureda, A., Flinn, I. W., Vandenberghe, P., Song, K. W., Dickinson, M., . . . Westin, J. R. (2022). Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine, 386(7), 640–654. https://doi.org/10.1056/NEJMoa2116133

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., . . . Reagan, P. M. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 382(14), 1331–1342. https://doi.org/10.1056/NEJMoa1914347

Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., O'Dwyer, K. M., Arellano, M. L., Lin, Y., Baer, M. R., Schiller, G. J., Park, J. H., Subklewe, M., Abedi, M., Minnema, M. C., . . . Houot, R. (2021). KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, 398(10299), 491–502. https://doi.org/10.1016/s0140-6736(21)01222-8

Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., . . . Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396(10254), 839–852. https://doi.org/10.1016/s0140-6736(20)31366-0

Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., Izutsu, K., Morschhauser, F., Lunning, M., Maloney, D. G., Crotta, A., Montheard, S., Previtali, A., Stepan, L., Ogasawara, K., . . . Abramson, J. S. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), 2294–2308. https://doi.org/10.1016/s0140-6736(22)00662-6

Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N., Dubowy, R., D'Andrea, A., Wang, L., . . . Gordon, L. I. (2022). Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncology, 23(8), 1066–1077. https://doi.org/10.1016/s1470-2045(22)00339-4

Munshi, N. C., Anderson, L. D., Jr., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., . . . San-Miguel, J. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705–716. https://doi.org/10.1056/NEJMoa2024850

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., . . . Giralt, S. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388(11), 1002–1014. https://doi.org/10.1056/NEJMoa2213614

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., . . . Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet, 398(10297), 314–324. https://doi.org/10.1016/s0140-6736(21)00933-8

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N., Dytfeld, D., Sidana, S., . . . Einsele, H. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379

Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018). FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist, 23(8), 943–947. https://doi.org/10.1634/theoncologist.2018-0028

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., Boughan, K., Hillian, A., Reese-Koc, J., Maschan, M., Dropulic, B., Sekaly, R. P., & de Lima, M. (2021). Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Frontiers in Immunology, 12, 745320. https://doi.org/10.3389/fimmu.2021.745320

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., . . . Brentjens, R. (2014). Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Transplantation and Cellular Therapy, 6(224), 224ra225. https://doi.org/10.1126/scitranslmed.3008226

Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018). Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit ‘ALL.’ Nature Reviews. Clinical Oncology, 15(4), 218. https://doi.org/10.1038/nrclinonc.2018.19

Article  PubMed  Google Scholar 

Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., Song, Y., Zhao, Y., & Tong, C. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 10(2), 15. https://doi.org/10.1038/s41408-020-0280-y

Article